Current landscape of direct-to-consumer genetic testing and its role in ophthalmology: a review

  • P.G. Sanfilippo
  • , L.S. Kearns
  • , P. Wright
  • , David Mackey
  • , Alex Hewitt

Research output: Contribution to journalArticlepeer-review

Abstract

© 2015 Royal Australian and New Zealand College of Ophthalmologists. The sequencing of the human genome has seen the emergence of the direct-to-consumer (DTC) genetic-testing market, which allows individuals to obtain information about their genetic profile and its many health and lifestyle implications. Genetics play an important role in the development of many eye diseases, however, little information is available describing the influence of the DTC industry in ophthalmology. In this review, we examined DTC companies providing genetic test products for eye disease. Of all eye conditions, the majority of DTC companies provided susceptibility testing or risk assessment for age-related macular degeneration (AMD). For the 15 companies noted to offer products, we found considerable variation in the cost, scope and clarity of informational content of DTC genetic testing for ophthalmic conditions. The clinical utility of these tests remains in question, and the American Academy of Ophthalmology recommendations against routine testing for many conditions probably still apply.
Original languageEnglish
Pages (from-to)578-590
JournalClinical and Experimental Ophthalmology
Volume43
Issue number6
Early online date27 Apr 2015
DOIs
Publication statusPublished - Aug 2015

Fingerprint

Dive into the research topics of 'Current landscape of direct-to-consumer genetic testing and its role in ophthalmology: a review'. Together they form a unique fingerprint.

Cite this